AI assistant
CAMBIUM BIO LIMITED — Capital/Financing Update 2017
Aug 28, 2017
64666_rns_2017-08-28_fd917fca-0dd8-43da-8db8-b7bd48e27738.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [282 x 128] intentionally omitted <==
==> picture [160 x 33] intentionally omitted <==
ASX Announcement
Regeneus receives R&D tax incentive of $2.6m
Sydney, Australia – 29 August 2017
Regeneus (ASX: RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.6m from the Australian Government’s Research and Development tax incentive program for activities conducted during the financial year 2017.
The Research and Development (R&D) tax incentive encourages companies to engage in R&D and innovation, benefiting Australia, by providing a tax offset for eligible R&D activities.
ENDS
About Regeneus:
Regeneus Ltd is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.
Contact for further information:
Sandra McIntosh Company Secretary and Investor Relations Regeneus Ltd T: +61 2 9499 8010 E: [email protected] or go to http://www.regeneus.com.au
25 Bridge Street, Pymble, NSW 2073
Ph: +61 2 9499 8010 • Fax: +61 2 9499 8020 • www.regeneus.com.au • ABN 13 127 035 358